Active, not recruitingPhase 2NCT05007821
Linezolid Dosing Strategies in Drug-Resistant TB
Studying Primary pulmonary tuberculosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- Constance A. BensonThe University of California, San Diego
- Intervention
- Linezolid 600 mg(drug)
- Enrollment
- 138 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2026
Study locations (13)
- Gaborone CRS (Site ID: 12701), Gaborone, South-East District, Botswana
- Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS (Site ID: 12101), Rio de Janeiro, Brazil
- GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS (Site ID: 31730), Port-au-Prince, Haiti
- Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS (Site ID: 30022), Port-au-Prince, Haiti
- Barranco CRS (Site ID: 11301), Lima, Peru
- De La Salle Health Science Institute Angelo King Medical Research Center (DLSHSI-AKMRC) (Site ID: 31981), Cavite, Philippines
- Wits Helen Joseph Hospital CRS (Wits HJH CRS) (Site ID: 11101), Johannesburg, Gauteng, South Africa
- Durban International CRS (Site ID: 11201), Durban, KwaZulu-Natal, South Africa
- Rustenburg CRS (Site ID: 31684), Rustenburg, North West, South Africa
- University of Cape Town Lung Institute (UCTLI) CRS (Site ID: 31792), Cape Town, Western Cape, South Africa
- South African Tuberculosis Vaccine Initiative (SATVI) CRS (Site ID: 31793), Cape Town, Western Cape, South Africa
- Thai Red Cross AIDS Research Centre (TRC-ARC) CRS (Site ID: 31802), Pathum Wan, Bangkok, Thailand
- Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS (Site ID: 31784), Chiang Mai, Thailand
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05007821 on ClinicalTrials.govOther trials for Primary pulmonary tuberculosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07484490Effects of the Active Cycle of Breathing Technique With and Without Balloon Blowing Therapy in TuberculosisRiphah International University
- RECRUITINGPHASE3NCT07209761A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary TuberculosisOtsuka Pharmaceutical Development & Commercialization, Inc.
- RECRUITINGPHASE2NCT07170800A Phase 2b Clinical Study of JDB0131 Benzenesulfonate TabletsWestVac Biopharma Co., Ltd.
- RECRUITINGPHASE2NCT06192160Trial of Novel Regimens for the Treatment of Pulmonary TuberculosisNational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGPHASE2NCT06748937A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With EthionamideTASK Applied Science
- ACTIVE NOT RECRUITINGNANCT07186478I-FALMIN Albumin Supplement for Patients With Pulmonary TuberculosisHasanuddin University
- ACTIVE NOT RECRUITINGPHASE3NCT06649721Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese CohortHuashan Hospital
- RECRUITINGPHASE4NCT06476210The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary Infection of Multi-drug Resistant Tuberculosis (MDR-TB) or Rifampicin-Resistant Tuberculosis (RR-TB)Beijing Chest Hospital